Comparison of somatostatin receptor scintigraphy with 111In-DOTA-DPhe1-Tyr3-octreotide and chromogranin A assay results in patients with neuroendocrine tumours

被引：0
|
作者：
Rodrigues, M. [1 ]
Heute, D. [1 ]
Gabriel, M. [1 ]
Putzer, D. [1 ]
Griesmacher, A. [1 ]
Virgolini, I. [1 ]
机构：
[1] Hietzing Hosp, Inst Nucl Med, Vienna, Austria
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2007年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S175 / S175
页数：1
相关论文
共 50 条
  • [31] Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide:: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide
    Bangard, M
    Béhé, M
    Guhlke, S
    Otte, R
    Bender, H
    Maecke, HR
    Biersack, HJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (06) : 628 - 637
  • [32] Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide:: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide
    Decristoforo, C
    Cholewinski, W
    Donnemiller, E
    Riccabona, G
    Moncayo, R
    Mather, SJ
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (10) : 1580 - 1580
  • [33] In-111-DTPA-DGlu1-minigastrin in comparison to In-111-DTPA-DPhe1-octreotide in 87 patients with neuroendocrine tumors
    Gotthardt, M
    Béhé, MP
    Rinke, A
    Herbst, B
    Pfestroff, A
    Goecke, J
    Heinis, J
    Arnold, R
    Behr, TM
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S214 - S215
  • [34] Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy
    De Jong, M
    Bakker, WH
    Breeman, WAP
    Bernard, BF
    Hofland, LJ
    Visser, TJ
    Srinivasan, A
    Schmidt, M
    Béhé, M
    Mäcke, HR
    Krenning, EP
    INTERNATIONAL JOURNAL OF CANCER, 1998, 75 (03) : 406 - 411
  • [35] Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours
    Helisch, A
    Förster, GJ
    Reber, H
    Buchholz, HG
    Arnold, R
    Göke, B
    Weber, MM
    Wiedenmann, B
    Pauwels, S
    Haus, U
    Bouterfa, H
    Bartenstein, P
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (10) : 1386 - 1392
  • [36] Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-d-Phel-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide
    C. Decristoforo
    W. Cholewinski
    E. Donnemiller
    G. Riccabona
    R. Moncayo
    S.J. Mather
    European Journal of Nuclear Medicine, 2000, 27 : 1580 - 1580
  • [37] Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours
    Andreas Helisch
    Gregor J. Förster
    Helmut Reber
    Hans-Georg Buchholz
    Rudolf Arnold
    Burkhard Göke
    Matthias M. Weber
    Bertram Wiedenmann
    Stanislas Pauwels
    Ulrike Haus
    Hakim Bouterfa
    Peter Bartenstein
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : 1386 - 1392
  • [38] The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
    Barbara Stolz
    Gisbert Weckbecker
    Peter M. Smith-Jones
    Rainer Albert
    Friedrich Raulf
    Christian Bruns
    European Journal of Nuclear Medicine, 1998, 25 : 668 - 674
  • [39] Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors
    Ugur, Ö
    Kothari, PJ
    Finn, RD
    Zanzonico, P
    Ruan, S
    Guenther, I
    Maecke, HR
    Larson, SM
    NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (02) : 147 - 157
  • [40] The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours
    Stolz, B
    Weckbecker, G
    Smith-Jones, PM
    Albert, R
    Raulf, F
    Bruns, C
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (07) : 668 - 674
12345